ArticleCureus2024
Paccianon the Neglected Galenic Drug for Ophthalmic Lesions.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Greco-Roman physician Galen of Pergamon was the first to mention a drug named Paccianon. This drug was unknown in ancient Greece and most probably through the School of Alexandria entered medical literature. Oribasius and Aetius were the only two practitioners who mentioned it after Galen, administrating it in various forms, such as poultice, mixture, and collyrium, for a series of ophthalmic diseases and cutaneous lesions. Modern medicine uses some of the material used in Paccianon's formula, proving its anticancer, antimicrobial, and anti-inflammatory properties. Paccianon constitutes one more example of the past that is significant in contemporary pharmaceutical chemistry. The drug was neglected through time, but its formula testified to the deep knowledge of the ancient Greeks in the botanical and mineral properties of various materials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.